Table 6.
Association between NSAID use and adenomatous polyp size
| Adenomatous Polyp* | ||||||
|---|---|---|---|---|---|---|
| NSAID use | Controls | n | ≥ 1 cm | N | < 1 cm | |
| Never | 1654 | 174 | 1.00 | 571 | 1.00 | |
| Baby aspirin only | 701 | 80 | 0.71 (0.52–0.97) | 253 | 0.81 (0.67–0.98) | |
| Regular aspirin only | 352 | 39 | 0.64 (0.43–0.95) | 137 | 0.75 (0.59–0.95) | |
| Non-aspirin NSAIDs only | 343 | 13 | 0.27 (0.15–0.48) | 112 | 0.80 (0.63–1.03) | |
| COX-2 inhibitor only | 77 | 3 | 0.34 (0.10–1.13) | 18 | 0.70 (0.41–1.22) | |
| Any combination of NSAIDS | 304 | 20 | 0.37 (0.22–0.62) | 105 | 0.66 (0.51–0.86) | |
| Aspirin only, doses/week | ||||||
| Never | 1654 | 174 | 1.00 | 571 | 1.00 | |
| < 7 | 119 | 8 | 0.60 (0.28–1.27) | 44 | 0.96 (0.65–1.40) | |
| 7 | 824 | 88 | 0.65 (0.48–0.87) | 303 | 0.77 (0.65–0.93) | |
| > 7 | 110 | 23 | 1.13 (0.68–1.90) | 43 | 0.78 (0.53–1.14) | |
| ρtrend | 0.006 | 0.02 | ||||
| Single agent non-aspirin NSAID, doses/week | ||||||
| None | 1654 | 174 | 1.00 | 571 | 1.00 | |
| < 7 | 81 | 2 | 0.27 (0.07–1.13) | 25 | 0.95 (0.59–1.54) | |
| 7 | 124 | 7 | 0.42 (0.19–0.94) | 38 | 0.83 (0.56–1.22) | |
| > 7 | 215 | 7 | 0.21 (0.09–0.46) | 67 | 0.72 (0.52–0.98) | |
| ρtrend | < 0.0001 | 0.18 | ||||
| Any combination of NSAID, doses/week | ||||||
| Never | 1654 | 174 | 1.00 | 571 | 1.00 | |
| < 7 | 38 | 7 | 1.25 (0.52–3.04) | 14 | 0.79 (0.41–1.51) | |
| 7 | 85 | 5 | 0.32 (0.12–0.83) | 39 | 0.95 (0.63–1.45) | |
| > 7 | 181 | 8 | 0.23 (0.11–0.50) | 52 | 0.51 (0.36–0.72) | |
| ρtrend | 0.0003 | 0.002 | ||||
*
Adjusted for age, gender, race, family history, education level, body mass index, energy intake, smoking status, alcohol use, physical activity, use of hormone replacement therapy, indication for colonoscopy, study site, and year of study enrollment